|Bid||0.73 x 15918400|
|Ask||0.74 x 844400|
|Day's range||0.72 - 0.76|
|52-week range||0.59 - 1.54|
|PE ratio (TTM)||N/A|
|Earnings date||19 Feb. 2018 - 23 Feb. 2018|
|Forward dividend & yield||0.00 (6.85%)|
|1y target est||0.73|
The Mayne Pharma Group Ltd (ASX:MYX) share price is one of three that have been beaten down over the last 12 months. Should you snap up shares?
Drugs manufacturer Mayne Pharma is still feeling the impact of tough competition and lower prices in the generic drugs market in the US, but expects the release of new drugs and restructuring initiatives will boost the company's financial performance. Chief executive Scott Richards says the company's first half is expected to be "soft" but that a range of initiatives is already yielding benefits. Shares in Mayne Pharma dropped 1.5 cents, or 2.4 per cent, to 61 cents.
Mayne Pharma's revenue for the first four months of the financial year dropped 12 per cent due to price deflation in the US generic marketplace. Chief executive Scott Richards says group revenue to the ...